Handok announced on the 24th that it has signed an exclusive domestic sales and distribution agreement with India's Biocon for the liraglutide-based obesity treatment drug Saxenda.
Saxenda is an obesity treatment drug in the glucagon-like peptide (GLP)-1 class developed by Novo Nordisk. Biocon recently received approval last month for a biosimilar of Saxenda. Through this agreement, Handok plans to handle the domestic product approval, sales, and distribution of liraglutide-based obesity treatment drugs. In terms of the drug, the plan is to seek approval as a data-submission drug in the form of a synthetic chemical drug rather than the existing protein-based biologics.
Kim Young-jin, Chairman of Handok, said, “Liraglutide was mainly used as a diabetes treatment but has gained significant attention as it was launched as an obesity treatment ingredient,” adding, “Through cooperation with Biocon, Handok can expand its portfolio into the obesity field.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
